Artículo
Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model
Garabalino, Marcela Alejandra; Heber, Elisa Mercedes; Monti Hughes, Andrea
; González, Sara Josefina
; Molinari, Ana Julia
; Pozzi, Emiliano César Cayetano; Nievas, Susana Isabel; Itoiz, María Elina
; Aromando, Romina Flavia; Nigg, David W.; Bauer, William; Trivillin, Verónica Andrea
; Schwint, Amanda Elena
Fecha de publicación:
04/2013
Editorial:
Springer Heidelberg
Revista:
Radiation and Environmental Biophysics
ISSN:
0301-634X
e-ISSN:
1432-2099
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Boron neutron capture therapy (BNCT) is based on selective accumulation of 10B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg 10B/kg) was administered to tumor-bearing hamsters. Groups of 3–5 animals were killed humanely at nine time-points, 3–12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24–35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7–11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Garabalino, Marcela Alejandra; Heber, Elisa Mercedes; Monti Hughes, Andrea; González, Sara Josefina; Molinari, Ana Julia; et al.; Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model; Springer Heidelberg; Radiation and Environmental Biophysics; 52; 3; 4-2013; 351-361
Compartir
Altmétricas